Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection

被引:5
|
作者
Debarry, Jennifer [1 ]
Cornberg, Markus [2 ,3 ]
Manns, Michael P. [1 ,2 ,3 ]
机构
[1] Helmholtz Ctr Infect Res GmbH, Braunschweig, Germany
[2] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[3] German Ctr Infect Res, Partner Site Hannover, Braunschweig, Germany
关键词
access to prophylaxis and treatment; Hepatitis B; linkage to care; screen-and-treat-programs; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; PREVENTION; VACCINATION; DIAGNOSIS; HBSAG; HBV; SEROPREVALENCE; CHEMOTHERAPY; REACTIVATION;
D O I
10.1111/liv.13320
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [1] Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection - The German Guideline
    Cornberg, M.
    Protzer, U.
    Petersen, J.
    Wedemeyer, H.
    Berg, T.
    Jilg, W.
    Erhardt, A.
    Wirth, S.
    Sarrazin, C.
    Dollinger, M. M.
    Schirmacher, P.
    Dathe, K.
    Kopp, I. B.
    Zeuzem, S.
    Gerlich, W. H.
    Manns, M. P.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2011, 49 (07): : 871 - 930
  • [2] Hepatitis B infection-therapy-prophylaxis
    Diel, R.
    [J]. GESUNDHEITSWESEN, 2007, 69 (06) : 344 - 344
  • [3] Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: The German guidelines for the management of HBV infection
    Cornberg, M.
    Protzer, U.
    Dollinger, M. M.
    Petersen, J.
    Wedemeyer, H.
    Berg, T.
    Jilg, W.
    Erhardt, A.
    Wirth, S.
    Schirmacher, P.
    Fleig, W. E.
    Manns, M. P.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (12): : 1281 - 1328
  • [4] Delineating the global challenges of hepatitis B virus infection
    Dusheiko, Geoffrey
    Agarwal, Kosh
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 372 - 373
  • [5] Antisense therapy of hepatitis B virus infection
    Wolf-Bernhard Offensperger
    Silke Offensperger
    Hubert E. Blum
    [J]. Molecular Biotechnology, 1998, 9 : 161 - 170
  • [6] Future therapy for hepatitis B virus infection
    Minami M.
    [J]. Clinical Journal of Gastroenterology, 2015, 8 (4) : 167 - 171
  • [7] Drug therapy - Hepatitis B virus infection
    Dienstag, Jules L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14): : 1486 - 1500
  • [8] Antisense therapy of hepatitis B virus infection
    Offensperger, WB
    Offensperger, S
    Blum, HE
    [J]. MOLECULAR BIOTECHNOLOGY, 1998, 9 (02) : 161 - 170
  • [9] Hepatitis B and C Re-infection: Prophylaxis and Therapy
    Bahra, M.
    Seehofer, D.
    Neumann, U. P.
    Berg, T.
    [J]. GASTROENTEROLOGE, 2009, 4 (06): : 526 - 539
  • [10] Prophylaxis in hepatitis B virus
    Buti, M
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2004, 96 (07) : 515 - 515